EBIT at other companies
Other financials
Where this comes from
Calculated from Enliven Therapeutics’s reported figures.
Plus components not separately reported this period.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's EBIT?
- Enliven Therapeutics (ELVN) reported EBIT of -$27.82M in Q1 2026.
- How has Enliven Therapeutics's EBIT changed year-over-year?
- Enliven Therapeutics's EBIT increased by 12.2% year-over-year, from -$31.69M to -$27.82M.
- What is the long-term trend for Enliven Therapeutics's EBIT?
- Over 4 years (2021 to 2025), Enliven Therapeutics's EBIT has grown at a 23.5% compound annual growth rate (CAGR), from -$51.44M to -$119.66M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.